Reliance Global Group, Inc.已正式签署具有约束力的条款书，拟收购以色列人工智能诊断技术企业Scentech Medical的控股权。此次战略收购将推动该公司切入价值数千亿美元的早期疾病检测赛道，通过整合Scentech开发的突破性AI驱动嗅觉诊断平台，构建精准医疗领域的核心竞争力。
Scentech的核心技术可通过分析人体呼出气体中的生物标志物，实现对癌症、神经系统疾病等重症的早期非侵入式筛查。其AI算法能识别特定气味分子与疾病间的关联，检测精度达到医疗级标准。这项交易不仅完善了Reliance Global Group在健康科技领域的产业链布局，更标志着其向高增长性诊断蓝海市场的关键一跃。
市场分析师指出，全球早期疾病检测市场年均复合增长率预计将超过15%，尤其在人工智能与分子诊断交叉领域存在巨大增量空间。通过此次收购，Reliance Global Group有望将Scentech的便携式检测设备与其现有保险业务网络形成协同效应，打造"检测+保险"的闭环商业模式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.